Vedolizumab is named as a drug or biological intervention in 15 clinical trials in our USA, China, UK and Ireland trial registers, 13 of which are recruiting. Lead sponsors include Takeda (10), Second Affiliated Hospital, Zhejiang University, School of Medicine (2) and AbbVie (1). Registered phases: Phase 3, Phase 4, Phase 2 and Observational. Conditions studied include Ulcerative Colitis; Crohn's Disease; Locally Advanced Non-Small Cell Lung Cancer (NSCLC).
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ulcerative Colitis | 8 |
| Crohn's Disease | 7 |
| Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | 1 |
| Metastatic Non-Small Cell Lung Cancer (NSCLC) | 1 |
| Crohn's Disease (CD) | 1 |
| Moderately to Severely Active Ulcerative Colitis | 1 |
| Inflamatory Bowel Disease | 1 |
| Crohn Disease (CD) | 1 |
| Lead sponsor | Trials |
|---|---|
| Takeda | 10 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| AbbVie | 1 |
| Bristol-Myers Squibb | 1 |
| Shanghai 10th People's Hospital | 1 |
| Register | Vedolizumab trials |
|---|---|
| Clinical trials in USA | 10 |
| Clinical trials in China | 9 |
| Clinical trials in UK | 5 |
| Clinical trials in Ireland | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vedolizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vedolizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.